IQVIA (NYSE:IQV) Price Target Raised to $303.00

IQVIA (NYSE:IQV) had its price objective boosted by Stifel Nicolaus from $276.00 to $303.00 in a research report released on Wednesday, Marketbeat reports. Stifel Nicolaus currently has a buy rating on the medical research company’s stock.

Several other research firms have also issued reports on IQV. HSBC reaffirmed a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. TD Cowen lifted their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. BMO Capital Markets boosted their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, William Blair upgraded IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $276.00.

IQVIA Stock Performance

IQVIA stock opened at $267.00 on Wednesday. The company’s 50-day moving average price is $260.76 and its 200-day moving average price is $212.85. IQVIA has a twelve month low of $154.50 and a twelve month high of $277.40. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $43.95 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.35 and a beta of 1.17.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts forecast that IQVIA will post 11.56 EPS for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock worth $3,796,021 in the last three months. 1.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $2,811,292,000. Dimensional Fund Advisors LP grew its position in IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after acquiring an additional 66,643 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in IQVIA by 9.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in IQVIA in the second quarter worth $240,911,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in IQVIA by 8.3% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company’s stock worth $209,057,000 after purchasing an additional 93,779 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.